Single-cell transcriptome sequencing (scRNA-seq) is currently the most widely used single-cell sequencing technology. It performs reverse transcription, amplification and high-throughput sequencing of the mRNA of a single cell. According to the transcription profile Similarities can distinguish different cell types and even reveal new cell types.

The global Single-cell Transcriptome Sequencing market size is projected to grow from US$ million in 2024 to US$ million in 2030; it is expected to grow at a CAGR of % from 2024 to 2030.

ReportPrime's newest research report, the “Single-cell Transcriptome Sequencing Industry Forecast” looks at past sales and reviews total world Single-cell Transcriptome Sequencing sales in 2022, providing a comprehensive analysis by region and market sector of projected Single-cell Transcriptome Sequencing sales for 2023 through 2029. With Single-cell Transcriptome Sequencing sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Single-cell Transcriptome Sequencing industry.

This Insight Report provides a comprehensive analysis of the global Single-cell Transcriptome Sequencing landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Single-cell Transcriptome Sequencing portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Single-cell Transcriptome Sequencing market.

This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Single-cell Transcriptome Sequencing and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Single-cell Transcriptome Sequencing.

United States market for Single-cell Transcriptome Sequencing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

China market for Single-cell Transcriptome Sequencing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Europe market for Single-cell Transcriptome Sequencing is estimated to increase from US$ million in 2023 to US$ million by 2030, at a CAGR of % from 2024 through 2030.

Global key Single-cell Transcriptome Sequencing players cover Aksomics, 10x Genomics, BD, BGI, Singleron Bio, etc. In terms of revenue, the global two largest companies occupied for a share nearly % in 2023.

This report presents a comprehensive overview, market shares, and growth opportunities of Single-cell Transcriptome Sequencing market by product type, application, key players and key regions and countries.

• Equipment
• Serve

• Cancer
• Immunology
• Neurology
• Others

This report also splits the market by region:

• United States
• Canada
• Mexico
• Brazil

• China
• Japan
• Korea
• Southeast Asia
• India
• Australia

• Germany
• France
• UK
• Italy
• Russia

• Egypt
• South Africa
• Israel
• Turkey
• GCC Countries

The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.

• Aksomics
• 10x Genomics
• BD
• BGI
• Singleron Bio
• Seekgene
• ThunderBio
• Tenk Genomics
• MobiDrop
• BioMarker
• Dynamic Biosystems
• M20 Genomics
• Illumina
• QIAGEN
• Q2 Solutions
• Novogene
• Oxford Nanopore Technologies
• PacBio
• Azenta Life Sciences
• Jingxin Biotechnology
• TaKaRa
• Bio-Rad
• Mission bio